2022 ICD-10-CM Code C57.4
Malignant neoplasm of uterine adnexa, unspecified
Valid for Submission
| ICD-10: | C57.4 |
| Short Description: | Malignant neoplasm of uterine adnexa, unspecified |
| Long Description: | Malignant neoplasm of uterine adnexa, unspecified |
Code Classification
C57.4 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of uterine adnexa, unspecified. The code C57.4 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C57.4 might also be used to specify conditions or terms like carcinosarcoma of uterine adnexa, malignant neoplasm of uterine adnexa, primary malignant neoplasm of uterine adnexa, primary mucinous carcinoma of uterine adnexa or primary serous carcinoma of uterine adnexa.
The code C57.4 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: adnexa (uterine) or uterus, uteri, uterine adnexa NEC .
Unspecified diagnosis codes like C57.4 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
- Diagnoses for females only - The Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, these edits apply to FEMALES only .
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Carcinosarcoma of uterine adnexa
- Malignant neoplasm of uterine adnexa
- Primary malignant neoplasm of uterine adnexa
- Primary mucinous carcinoma of uterine adnexa
- Primary serous carcinoma of uterine adnexa
Diagnostic Related Groups - MS-DRG Mapping
The ICD-10 code C57.4 is grouped in the following groups for version MS-DRG V39.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). applicable from 10/01/2021 through 09/30/2022.
| MS-DRG | MS-DRG Title | MCD | Relative Weight |
|---|---|---|---|
| 736 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC | 13 | 4.2582 |
| 737 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC | 13 | 2.0582 |
| 738 | UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC | 13 | 1.4766 |
| 739 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC | 13 | 3.8217 |
| 740 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC | 13 | 1.8 |
| 741 | UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC | 13 | 1.2795 |
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C57.4 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C57.4 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
- 183.9 - Mal neo adnexa NOS (Approximate Flag)
Table of Neoplasms
The code C57.4 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
| Neoplasm, neoplastic | Malignant Primary |
Malignant Secondary |
CaInSitu | Benign | Uncertain Behavior |
Unspecified Behavior |
|---|---|---|---|---|---|---|
| »adnexa (uterine) | C57.4 | C79.89 | D07.39 | D28.7 | D39.8 | D49.59 |
| »uterus, uteri, uterine »adnexa NEC | C57.4 | C79.82 | D07.39 | D28.7 | D39.8 | D49.59 |
Information for Patients
Uterine Cancer
The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.
The symptoms of uterine cancer include
- Abnormal vaginal bleeding or discharge
- Trouble urinating
- Pelvic pain
- Pain during intercourse
Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.
Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Code History
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)